Business
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
Key findings support weekly induction of immune cell trafficking by Decoy20, a critical factor in effective cancer immunotherapyNEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of Decoy20. As announced in last week’s earnings relea
About this update from Indaptus Therapeutics, Inc.
[{"type":"image","alt":"Indaptus Therapeutics","displaySize":"","headline":null,"caption":"Indaptus Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":226,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/9c09e008af85eb0969fb44cb8570a245"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BUI5bQ5PWkG2QG7XsTNFvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9c09e008af85eb0969fb44cb8570a245","width":226,"height":60}},"lazy":false},{"type":"text","content":"Key findings support weekly induction of immune cell trafficking by Decoy20, a critical factor in effective cancer immunotherapy","length":128,"tagName":"p"},{"type":"text","content":"NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of Decoy20.","length":329,"tagName":"p"},{"type":"text","content":"As announced in last week’s earnings release, the Company has now enrolled more than 20 patients in the weekly dosing cohort, marking a key milestone in the trial. Initial data indicate that Decoy20 at the 30 million cell dose was generally well-tolerated, with a favorable safety profile and promising early signs of clinical benefit, including some patients demonstrating stable disease. Additionally, Decoy20 triggered short-term increases in multiple key immune system biomarkers (cytokines and chemokines), which play a crucial role in activating the body’s natural defenses against cancer.","length":595,"tagName":"p"},{"type":"text","content":"Today, Indaptus is reporting further insights showing that weekly Decoy20 treatment also leads to broad, blood-based immune cell trafficking. This immune cell movement, which includes transient weekly increases and decreases in the levels of major innate and adaptive immune cell types in the blood, is an important pharmacodynamic marker, indicating that immune cells are actively mobilizing from bone marrow and/or trafficking to tissues.","length":440,"tagName":"p"},{"type":"text","content":"Michael Newman, Founder and Chief Scientific Officer of Indaptus, commented, “Immune cell movement – or trafficking to and...